Personalizing treatment for malignant pleural mesothelioma

Quispel-Janssen, J.M.M.F.

CHAPTER 6

6

PD-1 blockade with Nivolumab in Patients with Recurrent Malignant Pleural Mesothelioma

Josine Quispel-Janssen MD[a*] | Vincent van der Noort PhD[b] | Jeltje F. de Vries PhD [b] | Marion Zimmerman[a] | Ferry Lalezari MD[c] | Erik Thunnissen MD PhD[d] | Kim Monkhorst MD PhD[e] | Robert Schouten MD[a] | Laurel Schunselaar MS[g] | Maria Disselhorst MD[a] | Houke Klomp MD PhD[f] | Sjaak Burgers MD PhD[a] | Wieneke Buikhuisen MD[a] | Paul Baas MD PhD[a]

[a] Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
[b] Biometrics Department, Netherlands Cancer Institute, Amsterdam, The Netherlands
[c] Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
[d] Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands
[e] Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
[f] Department of Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands
[g] Division of Oncogenomics, Oncode Institute within Netherlands Cancer Institute, Amsterdam, The Netherlands

Journal of Thoracic Oncology, June 2018

Abstract

Background: Malignant Pleural Mesothelioma (MPM) has limited treatment options and a poor outcome. PD-1/PD-L1 checkpoint inhibitors have proven efficacious in several cancer types. Nivolumab is a fully humanized monoclonal antibody against PD-1 with a favorable toxicity profile. In MPM, the immune system is considered to play an important role. We therefore tested nivolumab in recurrent MPM.

Methods: In this single center trial, patients with MPM received nivolumab 3mg/kg i.v. every two weeks. Primary endpoint was the disease control rate (DCR) at 12 weeks. Pre- and on-treatment biopsies were taken to analyze biomarkers for response.

Results: Of the 34 patients included, eight patients (24%) had a partial response at 12 weeks and another eight had stable disease (SD) resulting in a DCR at 12 weeks of 47%. One reached a PR at 18 weeks. In four patients with SD, the tumor remained stable for more than 6 months. Treatment-related adverse events (TR-AE) of any grade occurred in 26 patients (76%), most commonly fatigue (29%) and pruritus (15%). Grade 3 and 4 TR-AE were reported in 9 patients (26%), with pneumonitis, gastro-intestinal disorders and laboratory disorders mostly seen. One treatment-related death was due to pneumonitis and probably initiated by concurrent amiodarone therapy. PD-L1 was expressed on tumor cells in 9 samples (27%), but did not correlate with outcome.

Interpretation: Single agent nivolumab has meaningful clinical efficacy and a manageable safety profile in pretreated patients with mesothelioma. PD-L1 expression does not predict for response in this population.

Keywords: Mesothelioma; Immunotherapy; PD-L1; Nivolumab; Checkpoint Inhibitor

Introduction

Malignant Pleural Mesothelioma (MPM) is an aggressive tumor arising from mesothelial cells of the pleural cavity and is strongly related to (occupational) asbestos exposure. Although the use of asbestos is banned in most western countries, this disease will continue to score victims over the next decade, due to the long latency time [1].

MPM is refractory to the vast majority of drugs and has a dismal prognosis: most patients die within two years after diagnosis. The standard treatment for patients with advanced disease is chemotherapy consisting of a platinum- anti-folate combination [2]. There is no registered second-line therapy, since no study demonstrated a survival benefit in this setting [3]. Improving outcome is urgently needed, but remains a huge challenge due to the difficulty of response evaluation and the heterogeneity of the disease. The success of new treatment approaches such as immunotherapy in other cancer types, gives hope to these patients.

Immunotherapy enhances the ability of the patients own immune system to recognize and destroy tumor cells. Tumors can evade this immunosurveillance by upregulating inhibitory signals such as the PD-1/PD-L1 pathway [4]. Blockade of this pathway by PD-1 inhibitors resulted in long-lasting responses, as was first demonstrated in melanoma [5]. It has shown efficacy in many other cancer types, including lung cancer [6,7] and renal cell carcinoma [8].

Nivolumab (BMS-936558) is a fully human monoclonal antibody that binds PD-1 on activated immune cells and disrupts binding of PD-1 to its ligand PD-L1. This process will prevent downregulation of cytotoxic T-cells and augment the host-antitumor response. Nivolumab is registered in several countries for the treatment of advanced melanoma and is approved for the second-line treatment of NSCLC after previous platinum-containing chemotherapy. To date, nivolumab shows a mild toxicity profile as hematologic toxicities are rare and the majority of non-hematological toxicities are low grade and manageable. The safety profile of nivolumab monotherapy is similar across tumor types.

In spite of all the positive reports about checkpoint inhibitors, not all tumors respond well to this treatment. Therefore, it is crucial to find predictive biomarkers that enable us to withhold treatment from patients that are unlikely to respond and thus prevent time loss and unwanted side effects. The most frequently studied biomarker is PD-L1 expression. In MPM, expression of PD-L1 was demonstrated by several groups, especially on sarcomatoid MPM [9-12]. PD-L1 expression is also present on immune cells as is assessed in several tumor types [13]. Emerging data reveal that other factors like mutational load, general immune status and the tumor micro-environment may play an important role in evoking a response. Therefore, we designed this single arm phase II trial with an emphasis on biomarker research.

Methods

Study design and participants

In this prospective, single arm, single center, phase II trial, a Simons' minimax design was used. Patients aged 18 years or older with MPM were eligible for study participation if they had disease recurrence after at least one chemotherapy regimen, WHO performance status 0 or 1, measurable disease and adequate liver, renal and bone marrow functions including lactate dehydrogenase (LDH). In addition, C-reactive protein (CRP), amylase, lipase, thyroid stimulating hormone (TSH) and free Thyroxine 4 (fT4) were measured. Tumors had to be accessible for repeated biopsies by thoracoscopy or a CT- or ultrasound guided transthoracic approach. Key exclusion criteria were symptomatic central nervous system (CNS) metastasis, autoimmune disease or systemic immunosuppressive therapy.

The study protocol was approved by the institutional ethics committee and conducted in accordance with the Good Clinical Practice guidelines and the Declaration of Helsinki. Written informed consent was obtained from all participants. The trial was registered at ClinicalTrials.gov, number NCT02497508.

Procedures

Treatment consisted of bi-weekly intravenous administration of Nivolumab 3mg/kg, a fully humanized IgG4 antibody targeting PD-1 (Opdivo, Bristol-Meyers Squibb). Dose and treatment schedule were based on data from a phase I trial [14]. No dose escalations or reductions were allowed. Dose delays were permitted for protocol-defined reasons. Treatment continued for a maximum of 1 year or until disease progression or unacceptable toxicity.

Tumor response was assessed with CT-scans every six weeks (every 8 weeks after 24 weeks of treatment) using a combination of Response Evaluation Criteria In Solid Tumors (RECIST) modified for mesothelioma [15] and RECIST modified for immunotherapeutic agents [16]. A partial response (PR) was defined as a decrease of ≥30% of the sum of target lesions, measured according to RECIST modified for mesothelioma (unidimensional measurements of tumor thickness perpendicular to the chest wall or the mediastinum). Progressive disease (PD) was defined as an increase of ≥20% of target lesions, confirmed by another CT-scan at least 4 weeks apart. Patients were allowed to continue treatment beyond initial radiologic progression in the absence of clinical deterioration. If the subsequent CT scan did not confirm progression, the initial progression was considered to be pseudoprogression, and the patient was allowed to continue treatment with nivolumab. New lesions did not define progression, but were added to the total sum of tumor burden, according to RECIST modified for immunotherapeutic agents. Non-target lesions could contribute to the designation of overall progression, but PD was never concluded solely on the basis of increased lymph nodes. Stable disease (SD) was defined as having neither complete response (CR), PR nor PD.

Laboratory testing was performed before each nivolumab administration. Pulmonary function was assessed at baseline and after 6 weeks. Tumor tissue specimens were obtained prior to and after 3 courses of nivolumab by means of thoracoscopy or ultrasound- or CT-guided transthoracic biopsies.
PD-L1 expression on formalin-fixed, paraffin-embedded tissue samples was assessed with immunohistochemistry using monoclonal antibody 28-8 according to the manufacturer (Dako Autolink PD-L1 28-8, Rb Monoclonal, detection with Rabbit Linker and Envision). At least 100 neoplastic cells were scored for membranous staining and a tissue sample was considered positive if more than 1% of tumor cells stained positive. Expression was quantified in five categories: 1-5% positive cells, 5-10%, 10-25%, 25-50% and ≥50% positive cells.

Outcomes
The disease control rate (DCR) at 12 weeks was the primary endpoint of this study. DCR was defined by the number of patients with CR, PR and SD, as a percentage of the total number of patients in the study. Secondary endpoints included DCR at 6 months, clinical benefit rate, objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and safety. Patients with CR, PR and patients with long-term SD (≥6 months) were considered to have clinical benefit. PFS was defined as the time interval from the date of start of treatment to the date of the first documented tumor progression or death due to any cause, whichever occurred first. OS was defined as the time interval from the date of start of treatment to the date of death due to any cause. Safety was assessed by incidence of adverse events, reported according to the NCI Common Terminology Criteria for Adverse Events, version 4.03.

Statistical analysis
Based on our hypothesis that treatment with nivolumab will increase the DCR at 12 weeks from 20 to 40%, a Simon mini-max design with a sample size of 33 patients was chosen with an interim analysis for futility after 18 patients, allowing the study to continue only if at least 5 of the first 18 patients had disease control. This design with an early stop for futility was chosen because of the limited number of patients with this rare tumor type. Treatment with Nivolumab was deemed successful if the study was not stopped at the interim analysis and at least 11 patients out of the 33 showed disease control. When the true DCR in the population is 40%, the chosen numbers guarantee that the power of declaring success will be 80% while the probability of making a type I error (defined as declaring success when the true DCR was 20% or less) is controlled at 0.05. PFS and OS were calculated using the Kaplan-Meier method. All patients that received at least one dose of nivolumab and had at least one radiologic evaluation were considered evaluable. All patients that received at least one dose of nivolumab and had at least one follow up visit were included in the safety analysis.

Cut-off for survival analysis was January 2018. Fisher's exact test was used to analyze the correlation between PD-L1 expression and response.

Role of the funding source
The study was designed by the authors and financially supported by Bristol-Meyers Squibb which included medication supply.

Results

Between July 2015 and June 2016, 38 patients gave informed consent. Of these, 34 patients fulfilled the entry criteria and received study treatment. Thirty-three patients were evaluated; one patient died due to cardiac disease prior to the response evaluation (Fig. 1). At the interim analysis, five out of 18 patients had a partial response and four had stable disease. Disease control was thus reached in more than 5 patients allowing the trial to continue. Baseline characteristics are shown in table 1. With a median age of 67 years, a male predominance (82%) and a majority of epithelial subtype, our study population was representative for the general mesothelioma population.



Figure 1. CONSORT Flow Diagram.

Table 1. Patient characteristics.

Demographic Variable	Patients (n=34)
Age, median in years (range)	67 (50-81)
Sex	
Male	28 (82%)
Female	6 (18%)
WHO performance score	
0	18 (53%)
1	16 (47%)
Histologic subtype	
Epithelioid	28 (82%)
Sarcomatoid	2 (6%)
Mixed	4 (12%)
Previous local therapy	
Surgery	3 (9%)
Radiotherapy	5 (15%)
Disease stage	
I-III	24 (71%)
IV	10 (29%)

Most patients received one prior line of systemic treatment; one patient received two lines. Pleurectomy/decortication was performed in four patients. Five patients received radiotherapy prior to start of study treatment. Median time from the initial diagnosis of mesothelioma to the start of study enrolment was 12.3 months. One quarter of patients started nivolumab treatment within 3 months after completing their previous chemotherapy. The median number of doses nivolumab administered was 7 (IQR 3 – 17.25) and the median duration of treatment was 2.8 months (95% CI 1.8 – 6). Dose delays occurred 11 times in 9 patients. In 7 cases in 6 patients this was due to toxicity. Administrative or personal requests caused the other dose delays. Post-study treatment was given in 9 patients (27%), mostly gemcitabine or vinorelbine.

At 12 weeks, a PR was observed in eight patients of the 34 in the intention to treat group (24%, 95% CI: 11% - 42%). Eight patients had SD, resulting in a DCR of 47% (95% CI: 30%-65%). Seventeen patients had PD after 12 weeks. One patient with SD at 12 weeks eventually reached a PR after 18 weeks resulting in a total of 9 patients (26%) with a PR. In four patients with SD at 12 weeks, the tumor remained stable for more than 6 months. In total, 13 patients (9 with PR and 4 with long-term SD; 39%) were considered to have clinical benefit from their treatment with nivolumab.
Three patients had an initial increase in tumor burden of more than 20% followed by a PR which was considered to be pseudoprogression.

The median follow up was 27.5 months (95% CI: 19.3-upper boundary of CI not attained); the minimum follow up was 1.9 months. Median time to response in the nine responders was 2.6 months (95% CI: 2.3-upper boundary of CI not attained). The median duration of response was 7.0 months (95% CI: >3.0). Two patients with a PR had to discontinue treatment due to adverse events (pneumonitis and pneumonitis in combination with nausea). Their responses lasted 3 and 8 months. One of the responding patients received only one dose of nivolumab. Five patients with clinical benefit discontinued study treatment after one year according to protocol rules, with two of them having ongoing clinical benefit. Responses and duration of treatment of all patients are visualized in the swimmer plot in figure 2.



Figure 2. Efficacy of Nivolumab in swimmerplot organized by treatment duration.

Median PFS was 2.6 months (95% CI: 2.23 – 5.49) and at six months, 29% of patients (95% CI 18% - 50%) were free of progression (figure 3A). Median OS was 11.8 months (95% CI:

9.7-15.7) (figure 3B). At 6 months the OS was 74% (95% CI 60% - 90%) and after one year 50% (95% CI: 36% - 70%).

Biomarkers

Pre-treatment biopsies were taken from all patients according to study protocol and 33 out of the 34 patients that received at least one course of nivolumab were evaluable for PD-L1 expression. PD-L1 expression on > 1% of tumor cells was seen in 9 samples (27%) of which 7 (78%) were epithelioid, 1 (11%) sarcomatoid and 1 (11%) mixed type. PD-L1 expression was positive in 4 of the 9 patients (44%) with a PR. Of all 13 patients that experienced clinical benefit 5 (38%) had PD-L1 expression while PD-L1 expression was demonstrated in 4 (20%) out of 20 patients without clinical benefit (Table 2A). On-treatment biopsies were obtained from 31 patients with 27 samples being evaluable. In four cases there was no accessible tumor left to biopsy, or no viable tumor was found in the specimen. Of the 13 patients with clinical benefit, 11 samples were evaluable and 3 (27%) were PD-L1 positive. Of the patients without clinical benefit, 3 out of 16 evaluable samples (19%) were PD-L1 positive (Table 2B). There was no correlation between PD-L1 expression in pre-treatment biopsies compared to on-treatment biopsies. PD-L1 expression in neither pre-treatment nor on-treatment biopsies correlated with outcome (p-values 0.43 and 0.66 respectively).



Figure 3. A Progression Free Survival
Figure 3. B Overall Survival

Table 2 PD-L1 Expression

Pre-treatment biopsy	PD-L1 + 1-5%	PD-L1 + 5-10%	PD-L1 + 10-25%	PD-L1 + 25-50%	PD-L1 + >50%	PD-L1 -	Biopsy not evaluable	Total
Clinical benefit +	1	0	0	2	2	8	0	13
Clinical benefit -	1	0	1	1	1	15	1	20
Pt not evaluable	0	0	0	0	0	1	0	1
Total	2	0	1	3	3	24	1	**34**

A PD-L1 expression in pre-treatment biopsies of 34 patients that were included. Patients with a PR and patients with long-term SD (≥6 months) were considered to have clinical benefit. Expression was quantified in five categories: 1-5% positive cells, 5-10%, 10-25%, 25-50% and ≥50% positive cells. PD-L1 expression did not correlate with outcome (p = 0.43).

On-treatment biopsy	PD-L1 + 1-5%	PD-L1 + 5-10%	PD-L1 + 10-25%	PD-L1 + 25-50%	PD-L1 + >50%	PD-L1 -	Biopsy not evaluable	Total
Clinical benefit +	2	0	0	0	1	8	2	13
Clinical benefit -	1	0	1	1	0	13	2	18
Pt not evaluable	0	0	0	0	0	0	3	3
Total	3	0	1	1	1	21	7	**34**

B PD-L1 expression in on-treatment biopsies. PD-L1 expression did not correlate with outcome (p = 0.66).

Blood biomarkers such as LDH, CRP, lymphocytes and neutrophil-to-lymphocyte ratio (NLR) were analyzed with respect to outcome. LDH, CRP, and absolute leucocyte count at baseline and at six weeks did not predict response or progressive disease. Neither was a change from baseline to week six in these parameters related to outcome. However, an increase in NLR of > 25% from baseline to week six correlated with non-response.

Toxicity

All 34 patients that started study treatment were included in the safety analysis. Treatment-related adverse events of any grade occurred in 26 patients (76%), most commonly fatigue (29%) and pruritus (15%) (Table 3). Grade 3 and 4 treatment related adverse events were reported in 9 (26%) patients. There was one treatment related death. This patient received amiodarone for atrial fibrillation and developed respiratory symptoms and radiologic changes, consistent with pneumonitis within 4 weeks after start of treatment. In retrospection, subtle signs of interstitial lung disease were already discernable prior to nivolumab treatment, which suggests that amiodarone initiated the pneumonitis. Both amiodarone and nivolumab were stopped immediately and the patient was treated with corticosteroids. Over the course of several weeks, he deteriorated and died, while at that time, disease progression was also suspected.

Table 3. Treatment-related Adverse Events.

Adverse Events	Any grade	Grade 3-4	Grade 5
Any	26 (76%)	9 (26%)	1 (3%)
General disorders			
Fatigue	10 (29%)	0	
Fever	3 (9%)	0	
Infusion related reaction	2 (6%)	0	
Pruritus	5 (15%)	0	
Allergic reaction	2 (6%)	1	
Respiratory disorders			
Pneumonitis	4 (12%)	2	1
Gastrointestinal disorders			
Nausea	3 (9%)	1	
Vomiting	1 (3%)	1	
Colitis	0 (0%)		
Laboratory abnormalities			
Liver biochemistry	2 (6%)	2	
Other			
Acute kidney injury	1 (3%)	1	
Pericardial effusion	1 (3%)	1	

Pneumonitis was reported in three other cases. One of these patients, who had a PR, developed grade 2 pneumonitis that resolved with corticosteroid treatment, but recurred after restart of nivolumab. Study treatment was therefore discontinued permanently. Two patients were admitted to the hospital with respiratory symptoms and radiologic changes suggestive of pneumonitis in combination with disease progression. After start of treatment with corticosteroids, both turned out to have pseudoprogression. One of the patients successfully restarted nivolumab after resolution of symptoms and had a PR that lasted 9.5 months. The other experienced worsening of his pre-existing nausea, simultaneously with his respiratory symptoms and therefore, study treatment was discontinued. In spite of discontinuation after only one course, he developed a PR. One patient died prior to response evaluation due to cardiac disease, unrelated to study treatment.

Discussion

Until now, results in second-line MPM therapy have been disappointing with response rates varying between 7 and 20% [3,17]. Our study shows that single agent nivolumab has promising anti-cancer activity in this PD-L1–unselected population of patients with progressive

MPM after previous systemic treatment. With a DCR of 47% at 12 weeks, our trial met its primary endpoint. In addition to the 9 patients with a PR, there were 4 patients that had SD for a period longer than six months, suggesting a clear clinical benefit. This makes the 26% ORR in this trial encouraging for a disease that is notoriously difficult to treat. At first glance, a median PFS of 2.6 months does not seem spectacular, but the median OS of 11.8 months is very promising in this cohort of pretreated patients. These results are in line with outcomes of other immuno-oncology trials where OS is mainly driven by a small group of patients with long lasting responses. Furthermore, our results are consistent with those of the recently published phase I study with pembrolizumab that reported a response rate of 20% [18]. Patients in that trial were selected to have more than 1% PD-L1 expression. The subsequent phase II study was performed in an unselected group of mesothelioma patients and showed a comparable response rate of 21% [19]. The reported DCR of 76% at 12 weeks in this pembrolizumab trial may look superior to our results, but the limited number of patients in these trials is likely to render the difference not significant. We consider the efficacy of pembrolizumab and nivolumab to be comparable as is the case in second-line studies in NSCLC [7,20]. The Javelin trial reported 9.4% responders with avelumab, a PD-L1 inhibitor. Thus far, there is no good explanation for this difference other than a variation in patient selection [21].

Despite a higher rate of pneumonitis, the safety profile in our study was similar to those noted in previous nivolumab trials and to the phase II study with pembrolizumab. The fatal case with pneumonitis was most likely initiated by use of amiodarone and enhanced by nivolumab. A detailed retrospective analysis of the CT scans identified a barely noticeable interstitial lung disease already present before start of nivolumab. Amiodarone is well known for its risk of drug interactions and pneumonitis. To our knowledge, this is the first observation of a fatal outcome of this combination. Of the three other patients with pneumonitis, only one had a typical presentation; two others had pneumonitis simultaneously with pseudoprogression, which is likely to have aggravated respiratory symptoms. All three cases recovered completely. Pseudoprogression was seen in 3 patients (9%), which is within the expected range [22]. We did not see any cases of hyperprogression as was recently defined as time-to-treatment failure (TTF) <2 months, >50% increase in tumor burden compared to pre-immunotherapy imaging, and >2-fold increase in progression pace [23,24]. Most adverse events were manageable with established guidelines.

PD-L1 expression as a biomarker of response has been analyzed in various studies using different antibodies and staining procedures. Studies comparing different PD-L1 assays, suggest that three assays do not differ a lot from each other (SP263, 28-8, 22C3), but none give 100% interchangeable results [25,26]. In our trial, the 28-8 assay was used showing PD-L1 expression in 27% of tumors, which is consistent with previous reports of MPM [9-12]. Responses were seen irrespective of PD-L1 expression and pre-treatment PD-L1 expression

did not correlate with on-treatment expression levels. Several clinical trials demonstrated that PD-L1 expressing tumors enrich for response [7,20]. However, PD-L1 is frequently expressed non-homogenously throughout a tumor, which may lead to sampling errors. In addition, PD-L1 expression on tumor cells can be a result of innate [27] or adaptive [28,29] immune resistance. In case of innate resistance, tumors express PD-L1 without the presence of active immune cells in the tumor micro-environment and as a consequence, PD-1 blockade will not be able to elicit a response. Both factors compromise the predictive value of PD-L1 expression as a biomarker.

Due to these concerns about PD-L1, several other biomarkers are currently evaluated for their predictive value in cancer immunotherapy. Blank and Haanen designed the Cancer Immunogram that takes into account parameters such as mutational load, lymphocyte count, CRP and LDH to describe a comprehensive immune status [30]. We investigated the possibility to predict response by using blood biomarkers, including a selection of biomarkers from the Cancer Immunogram. LDH, CRP and absolute lymphocyte count did not correlate with response in our patient set. However, a rise in NLR from baseline to week six did predict for non-response. None of the patients with an increase had a response except for one. In this patient, the rise in NLR was caused by use of corticosteroids which is known to induce an increase in neutrophil levels [31]. After discontinuation of corticosteroids, the NLR decreased sharply in this patient. NLR has prognostic value in several tumor types including MPM [32] but its merit as a predictive parameter has to be validated in a larger patient cohort. Since time to response is fairly long in immunotherapy, it may be convenient to have a marker that predicts non-response at an early time point in order to withhold a potentially toxic treatment. It should be noted however, that in our cohort no meaningful difference in NLR increase was observed between patients with progression and those with SD.

In conclusion, nivolumab has meaningful clinical activity and an acceptable safety profile in second line in an unselected population of patients with mesothelioma. Further studies with a combination of checkpoint inhibitors (ipilimumab and nivolumab) are ongoing.

References

1. LaDou J, Castleman B, Frank A, et al. The case for a global ban on asbestos. *Environmental health perspectives.* Jul 2010;118(7):897-901.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol.* Jul 15 2003;21(14):2636-2644.
3. Buikhuisen WA, Hiddinga BI, Baas P, van Meerbeeck JP. Second line therapy in malignant pleural mesothelioma: A systematic review. *Lung cancer.* Sep 2015;89(3):223-231.
4. Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. *The Journal of experimental medicine.* Apr 17 2006;203(4):883-895.
5. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *The New England journal of medicine.* Jul 11 2013;369(2):134-144.
6. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. *The New England journal of medicine.* Jul 9 2015;373(2):123-135.
7. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *The New England journal of medicine.* Oct 22 2015;373(17):1627-1639.
8. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. *The New England journal of medicine.* Nov 5 2015;373(19):1803-1813.
9. Mansfield AS, Roden AC, Peikert T, et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.* Jul 2014;9(7):1036-1040.
10. Cedres S, Ponce-Aix S, Zugazagoitia J, et al. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). *PloS one.* 2015;10(3):e0121071.
11. Khanna S, Thomas A, Abate-Daga D, et al. Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.* Aug 17 2016.
12. Combaz-Lair C, Galateau-Salle F, McLeer-Florin A, et al. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas. *Human pathology.* Jun 2016;52:9-18.
13. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. *Nature.* Nov 27 2014;515(7528):563-567.
14. Brahmer JR. PD-1-targeted immunotherapy: recent clinical findings. *Clinical advances in hematology & oncology : H&O.* Oct 2012;10(10):674-675.

15. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.* Feb 2004;15(2):257-260.
16. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clinical cancer research : an official journal of the American Association for Cancer Research.* Dec 1 2009;15(23):7412-7420.
17. Zucali PA, Simonelli M, Michetti G, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. *Lung cancer.* Mar 2012;75(3):360-367.
18. Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. *The Lancet. Oncology.* Mar 10 2017.
19. Kindler H KT, Tan YH, Rose B, Ahmad M, Straus C, Sargis R, Seiwert T. Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis. *Journal of Thoracic Oncology.* 2017;12(1):S293-S294.
20. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet.* Apr 9 2016;387(10027):1540-1550.
21. Hassan R TA, Manish R. Patel, John J. Nemunaitis, Jaafar Bennouna, John D. Powderly, Matthew H. Taylor, Afshin Dowlati, Franklin Chen, Joseph Leach, Ulka N. Vaishampayan, Claire F. Verschraegen, Jean-Pierre Delord, Hans Juergen Grote, Anja von Heydebreck, Jean-Marie Cuillerot, James L. Gulley. Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression. Paper presented at: ASCO2016.
22. Chiou VL, Burotto M. Pseudoprogression and Immune-Related Response in Solid Tumors. *J Clin Oncol.* Nov 1 2015;33(31):3541-3543.
23. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. *Clinical cancer research : an official journal of the American Association for Cancer Research.* Apr 15 2017;23(8):1920-1928.
24. Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A, Kurzrock R. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. *Clinical cancer research : an official journal of the American Association for Cancer Research.* Aug 1 2017;23(15):4242-4250.
25. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.* Feb 2017;12(2):208-222.

26. Thunnissen E, Allen TC, Adam J, et al. Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society. *Archives of pathology & laboratory medicine.* Mar 2018;142(3):408-419.
27. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nature reviews. Cancer.* Mar 22 2012;12(4):252-264.
28. Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. *Sci Transl Med.* Mar 28 2012;4(127):127ra137.
29. Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research.* Oct 1 2014;20(19):5064-5074.
30. Blank CU, Haanen JB, Ribas A, Schumacher TN. CANCER IMMUNOLOGY. The "cancer immunogram". *Science.* May 6 2016;352(6286):658-660.
31. Nakagawa M, Terashima T, D'Yachkova Y, Bondy GP, Hogg JC, van Eeden SF. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. *Circulation.* Nov 24 1998;98(21):2307-2313.
32. Kao SC, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research.* Dec 1 2010;16(23):5805-5813.